Tuesday, July 5, 2022
HomeNewsDEA Delays Production Of Marijuana Drug As Potential Treatment For MS And...

DEA Delays Production Of Marijuana Drug As Potential Treatment For MS And Huntington’s Disease

By Nina Zdinjak

MMJ International Holdings, in collaboration with a specialty pharmaceutical solutions company, has been manufacturing gelatin capsule medicines based on compounds found in cannabis. The company will investigate these in clinical trials as potential treatments for multiple sclerosis (MS) and Huntington’s disease (HD).

The Providens, Rhode Island-based medical cannabis research company had entered into a supply agreement with MMJ BioPharma Cultivation for them to supply strain specific marijuana plants for further processing to potentially obtain FDA approval for its drug.

The Connection Between Cannabis And Multiple Sclerosis
Photo by FilippoBacci/Getty Images

Problems With The DEA

MMJ BioPharma Cultivation applied for a DEA bulk manufacturing registration in 2018. The DEA application process is being delayed for years for reasons unknown. The DEA delay has negatively impacted the progression of the drug development for patients suffering from MS and HD.

RELATED: Effectively Treating Multiple Sclerosis With Cannabis Oil And Minimal Side Effects

“As MMJ International Holdings continues to advance to its clinical trials, these DEA delays are unprecedented,” stated Elio Mariani, PhD, MMJ’s executive responsible for research and development. “The statutory mandate of the DEA is security and divergence and to facilitate the manufacturing of pharmaceuticals to help patients suffering from chronic disease.”

Duane Boise, CEO of MMJ International Holdings commented, “MMJ’s clinical trials will provide patient dosing, safety, and efficacy data to the FDA to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking. We firmly believe that our MMJ oral gel cap medication, containing the marijuana plant’s unique pharmacological properties, will be FDA-approved as a safe and effective drug.”

RELATED: Cannabis For Tremors — What’s Working Right Now And What’s Not

MMJ International Holdings in 2019 was given DEA clearance to import cannabis-based products into the U.S. from Canada, a process that required the cooperation of multiple governmental agencies, including the FDA and the U.S. Drug Enforcement Agency (DEA) and Health Canada.

To date, five approved entities are currently listed on the DEA website but none are manufacturing a pharmaceutical such as MMJ International Holdings with filings with the FDA to perform clinical trials.

This article originally appeared on Benzinga and has been reposted with permission.

MUST READ

MORE BY THIS AUTHOR

Don't Miss Your Weekly Dose of The Fresh Toast.

Stay informed with exclusive news briefs delivered directly to your inbox every Friday.

We respect your privacy. Unsubscribe anytime.